Foghorn Therapeutics (FHTX) Income from Continuing Operations: 2019-2024

Historic Income from Continuing Operations for Foghorn Therapeutics (FHTX) over the last 6 years, with Dec 2024 value amounting to -$86.6 million.

  • Foghorn Therapeutics' Income from Continuing Operations rose 13.87% to -$16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.0 million, marking a year-over-year increase of 17.80%. This contributed to the annual value of -$86.6 million for FY2024, which is 11.99% up from last year.
  • Foghorn Therapeutics' Income from Continuing Operations amounted to -$86.6 million in FY2024, which was up 11.99% from -$98.4 million recorded in FY2023.
  • Over the past 5 years, Foghorn Therapeutics' Income from Continuing Operations peaked at -$69.5 million during FY2020, and registered a low of -$108.9 million during FY2022.
  • For the 3-year period, Foghorn Therapeutics' Income from Continuing Operations averaged around -$98.0 million, with its median value being -$98.4 million (2023).
  • Per our database at Business Quant, Foghorn Therapeutics' Income from Continuing Operations crashed by 47.58% in 2021 and then increased by 11.99% in 2024.
  • Over the past 5 years, Foghorn Therapeutics' Income from Continuing Operations (Yearly) stood at -$69.5 million in 2020, then tumbled by 47.58% to -$102.6 million in 2021, then dropped by 6.14% to -$108.9 million in 2022, then climbed by 9.60% to -$98.4 million in 2023, then increased by 11.99% to -$86.6 million in 2024.